Myconostica, the UK based medical diagnostic company developing and commercialising specific tests for life-threatening fungal infections, has received CE mark for its MycAssay Aspergillus for detection of Aspergillus DNA in serum.
MycAssay Aspergillus kit is a molecular diagnostic test designed to aid physicians for diagnosing Aspergillus in infected patients.
Myconostica claims that the test provides rapid and accurate results enabling appropriate drug treatments to be administered thereby improving patient outcomes.
Myconostica chief business officer John Thornback said that it is becoming increasingly recognised that Aspergillus DNA is present in serum and its measurement can be important in aiding the diagnosis of Aspergillus infections.
“There are a number of different high risk patient groups for whom it is difficult to obtain respiratory samples. The CE marking of MycAssay Aspergillus for serum now enables serum samples from these at risk patients to be tested using a fully validated assay,” Thornback said.